The cost of clinical trial data bias/loss, FDA’s new job and the need for bold leadership.
By Dr. Matthew Watson
The scandal of clinical trial data loss is eroding the fundamentals of evidence-based research and clinical medicine.
Before you right this post off as the stuff of conspiracy theories, fear-mongering, and 'alternative world views' consider that this view is shared by the likes of the FDA, the International Committee of Medical Journal Editors, the Cochrane Collaboration, and researchers at institutions like Johns Hopkins School of Medicine.
Here's the underlying premise as succinctly described by author Ben Goldacre:
"Drugs are tested by the people who manufacture them, in poorly designed trials, on hopelessly small numbers of weird, unrepresentative patients, and analysed using techniques that are flawed by design, in such a way that they exaggerate the benefits of treatments. Unsurprisingly, these trials tend to produce results that favour the manufacturer.
When trials throw up results that companies don't like, they are perfectly entitled to hide them from doctors and patients, so we only ever see a distorted picture of any drug's true effects. Regulators see most of the trial data, but only from early on in a drug's life, and even then they don't give this data to doctors or patients, or even to other parts of government. This distorted evidence is then communicated and applied in a distorted fashion."
Authors M. Todwin and J. Abramson summarize it thusly:
"Trials with positive results generally are published more frequently than studies that conclude that a new drug poses greater risks or is no more effective than standard therapy or a placebo. Furthermore, some articles may distort trial findings by omitting important data or by modifying prespecified outcome measures. Lack of access to detailed information about clinical trials can undermine the integrity of medical knowledge."
Here is a great list of very recent resources that may convince you of the merits of this concern:
- What doctors don't know about the drugs they prescribe (2012: TED video)
- The drugs don't work: a modern medical scandal (2012: The Guardian)
- Clinical Trial Data as a Public Good (2012: JAMA [subscription req'd])
- Registering Clinical Trial Results. The Next Step (2010: JAMA [subscription req'd])
- The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience (2012: Plos Medicine)
Source:
http://feeds.feedburner.com/CellTherapyBlog
- Commercialization of Regenerative Medicine: Learning from Spin-Outs - April 28th, 2013
- 2013 Annual Regenerative Medicine Industry Report - April 21st, 2013
- Cell Therapy Blog welcomes 2013 - January 6th, 2013
- The Accuracy of Adipose Stem Cell Doses - December 23rd, 2012
- A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments - December 16th, 2012
- The ROI on pant-wearing and other social media tips - December 16th, 2012
- Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. - December 2nd, 2012
- Cell Therapy Industry Group Welcomes its 4,000th member - November 11th, 2012
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. - November 4th, 2012
- CIRM addresses some tough questions. Is it all just glass towers and basic research? - October 21st, 2012
- Cell therapy portfolio outperforms major indices year-to-date - October 14th, 2012
- Anticipated short-term cell therapy industry clinical milestones - September 30th, 2012
- Two lessons I learned this week. - September 16th, 2012
- Are some cell counts too good to be true? Why some companies' product data may mislead. - September 2nd, 2012
- Is the cell therapy sector outperforming the major indices? - August 12th, 2012
- FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) - July 29th, 2012
- Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing - June 17th, 2012
- Industry-sponsored cardiovascular cell therapies. Some metrics. - May 27th, 2012
- Cell-based Cancer Immunotherapies. Some metrics.. - May 20th, 2012
- Another > $100M month for companies in the cell therapy space - May 6th, 2012
- Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? - March 11th, 2012
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? - January 1st, 2012
- Inactive and recently failed or terminated phase III or II/III cell therapy trials - December 18th, 2011
- Recently approved cell therapy products - December 18th, 2011
- Active phase III or II/III cell therapy trials - December 11th, 2011
- Sabrina Cohen Foundation Thanks Stem Cell Researchers - November 27th, 2011
- Commercializing Cell-based Regenerative Medicines - November 13th, 2011
- Cell Therapy & Regenerative Medicine Domains Available - September 25th, 2011
- Commercial-stage Cell Therapy Companies and Products - September 18th, 2011
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy - September 18th, 2011
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. - August 14th, 2011
- Clinical trial costs - July 31st, 2011
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations - July 10th, 2011
- In vivo cell trafficking just took a leap forward - July 3rd, 2011
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals - February 12th, 2011
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong - January 15th, 2011
- Careers in cell therapy & regenerative medicine - October 11th, 2010
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations - August 12th, 2010
- The changing face of PR and why it matters to regenmed - June 12th, 2010
- Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 - May 22nd, 2010
- Google to Invest in Regenerative Medicine - May 5th, 2010
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. - April 30th, 2010
- Stem cells for a Webby! - April 28th, 2010